Drug Trial Radar · NCT05857384
Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs
Last checked: Nov 20, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
Sep 8, 2023
Primary completion
Jul 31, 2024
Study completion Jul 31, 2024
Sponsor
- Lead sponsor
- Incannex Healthcare LtdIndustry
- Sponsor type
- Industry
- First posted
- May 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this randomised four-period cross-over Phase I study is to assess bioavailability, bioequivalence and tolerability of IHL-42X compared to the reference drugs in healthy volunteers. Volunteers will be enrolled and randomised to one of four treatment groups. Each group is to receive all four treatments in a twenty eight day cross-over study, with each treatment period running for seven days. The four treatment groups are described below; A = dronabinol 5 mg, fasted; B = acetazolamide 250 mg, fasted; C = IHL-42X (5 mg dronabinol, 250 mg acetazolamide), fasted; D = IHL-42X (5 mg dronabinol, 250 mg acetazolamide), fed. Each treatment group will enrol at least 29 participants each, for a total of at least 116 participants. Bioavailability and bioequivalence will assess and compare all four of the seven day treatments.
Conditions
- Obstructive Sleep Apnea
Interventions
IHL42XDrug
IHL-42X consists of acetazolamide and dronabinol.
Acetazolamide 250 MGDrug
A solid tablet containing 250 mg acetazolamide
Dronabinol 2.5 MGDrug
A soft gelatin capsules containing 2.5mg dronabinol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bioavailability of IHL-42XTime frame: 28 days
- Bioequivalence of IHL-42XTime frame: 28 days
- Effect of food on IHL-42X - maximum observed drug concentrationTime frame: 7 days
- Effect of food on IHL-42X - time of the maximum drug concentrationTime frame: 7 days
- Effect of food on IHL-42X - area under the drug concentration time curve from time zero to time of last measurable concentrationTime frame: 7 days
- Effect of food on IHL-42X - area under the drug concentration time curve from time zero to infinityTime frame: 7 days
- Effect of food on IHL-42X - area under the drug concentration time curve from time zero to 12 hoursTime frame: 7 days
- Effect of food on IHL-42X - area under the drug concentration time curve from time zero to 24 hoursTime frame: 7 days
- Effect of food on IHL-42X - the elimination half-lifeTime frame: 7 days
- Effect of food on IHL-42X - terminal elimination rate constantTime frame: 7 days
- Effect of food on IHL-42X - apparent total body clearanceTime frame: 7 days
- Effect of food on IHL-42X - apparent volume of distributionTime frame: 7 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
CMAX
Adelaide, South Australia, Australia
Nucleus Network Pty Ltd
Geelong, Victoria, Australia
Nucleus Network Pty Ltd [Commercial Road]
Melbourne, Victoria, Australia
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.